Last checked at 3 May 2012 12:21
3 May 2012 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or "the Company")
Admission of Open Offer Shares
Guildford, UK, 3 May 2012: On 3 April 2012, the Board of ReNeuron Group plc ("ReNeuron" or "the Company") announced the details of a Placing and Open Offer.
Following today's admission of the 17,387,116 New Ordinary Shares issued under the Open Offer, all shares issued in respect of the Placing and Open Offer have now been admitted for trading on AIM.
The total number of ordinary shares of 1p each in the Company in issue is now 774,827,700, with each share carrying the right to one vote. There are no shares held in Treasury. The above figures may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, ReNeuron under the FSA's Disclosure and Transparency Rules.
Enquiries:
ReNeuron | +44 (0) 1483 302560 |
Michael Hunt, Chief Executive Officer | |
Pat Huggins, Head of Finance
| |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Cowles
| |
Cenkos Securities | +44 (0) 20 7397 8900 |
Stephen Keys, Adrian Hargrave (NOMAD and Broker) | |
Andy Roberts (Sales) |
About ReNeuron
ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.